Immuneering Corp 8-K

What Happened
Immuneering Corporation (IMRX) filed an 8-K reporting the results of its Annual Meeting of Stockholders held June 11, 2026. A total of 44,495,059 shares of Class A common stock were present or represented by proxy (about 68.8% of outstanding Class A as of the April 15, 2026 record date). Peter Feinberg and Laurie B. Keating were elected as Class II directors to serve until the 2029 annual meeting. The stockholders also ratified the appointment of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.

Key Details

• Total shares present/represented: 44,495,059 (≈68.8% of Class A outstanding as of April 15, 2026).
• Director election votes:
  • Peter Feinberg — For: 26,420,287; Withheld: 2,008,073; Broker non-votes: 16,066,699.
  • Laurie B. Keating — For: 27,121,501; Withheld: 1,306,859; Broker non-votes: 16,066,699.
• Auditor ratification (RSM US LLP) — For: 42,142,848; Against: 1,920,218; Abstained: 431,993.

Why It Matters
These results confirm board continuity (two Class II directors elected through 2029) and formalize the independent auditor for 2026, both of which are governance items investors watch for oversight and financial reporting reliability. The sizable broker non-votes in the director elections indicate a material portion of shares did not vote on those items (but did not count against the nominees), while the auditor ratification received strong affirmative support from voting shares.